Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/249—Interferons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/16—Otologicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

• This invention relates to the treatment of autoimmune diseases.
• it concerns methods of treating Crohn's disease and/or psoriasis by administration of anti- interferon ⁇ antibodies.
• Psoriasis is one of the most common skin diseases, affecting up to 2 percent of the world population. It is a chronic inflammatory skin disorder clinically characterized by erythematous, sharply demarcated papules and rounded plaques covered by silvery micaceous scales. The skin lesions of psoriasis are variably pruritic. Traumatized areas often develop lesions of psoriasis (Koebner or isomorphic phenomenon). Additionally, other external factors may exacerbate psoriasis including infections, stress, and medications (e.g., lithium, beta blockers, and anti-malaria medications) (Harrison's Principles of Internal Medicine, 14th Edition, pp. 300 (1998)).
• infections, stress, and medications e.g., lithium, beta blockers, and anti-malaria medications
• Treatment of psoriasis depends on the type, location and extent of disease. Most patients with localized plaque-type psoriasis can be managed with midpotency topical glucocorticoids. However the long-term use of these agents is often accompanied by the loss of effectiveness. Ultraviolet light is an effective therapy for patients with widespread psoriasis. But long-term use of UV light may be associated with an increased incidence of squamous cell cancer of the skin (Harrison's Principles of Internal Medicine, 14 th Edition, pp. 300 (1998)).
• methotrexate is an effective agent, especially in patients with associated psoriatic arthritis.
• liver toxicity due to liver toxicity, its long-term use is limited for patients with widespread disease who are not responsive to less aggressive modalities.
• synthetic retinoid, etretinate has been shown to be effective in some patients with severe psoriasis, but it is a potent teratogen with an extremely long tissue half-life, thus precluding its use in women with childbearing potential (Harrison's Principles of Internal Medicine, 14 th Edition). Cyclosporine is also effective but its use is limited by its toxicity.
• Crohn's disease is an inflammation primarily of the small intestine that can also affect the esophagus, stomach, colon, and other organs and tissues. The prevalence of the disease in the United States is estimated at approximately 100 cases per 100,000 individuals. Symptoms of Crohn's disease include fever, abdominal pain, diarrhea, weight loss, and generalized fatigability. Recurrence is common and unpredictable, and severely affects the patient's quality of life. Current drug treatments for Crohn's disease include anti-inflammatory and immunosuppressive agents including antagonists of TNF- ⁇ such as Remicaide®. However, the response to these agents frequently decreases over time and the disease often becomes chronic, leading in many cases to repeated surgical intervention (Harrison's Principles of Internal Medicine, 14 th Edition, pp. 1643 (1998)).
• Interferon- ⁇ is a cytokine that functions in the regulation of the immune system and may lead to a type of immune response typical of autoimmune diseases. Increased production of interferon- ⁇ has been demonstrated in T-cells derived from the lamina intestinal of Crohn's disease patients' lesion, but not in the gut tissue with ulcerative colitis, and antibodies against interferon- ⁇ have been demonstrated to be effective in an animal model of Crohn's disease (Powrie, et. al., Immunity 1 : 553-562 (1994)). Serum levels of interferon ⁇ are significantly higher in psoriatic patients compared to normal subjects (Chodorowska G. J. Eur. Acad. Dermatol. Venereol.
• U.S. Patent No. 6,036,956 discloses a method for treating systemic lupus erythematosis by administering polyclonal or monoclonal antibodies specific for interferon ⁇ .
• U.S. Patent No. 6,333,032 and U.S. Patent No. 6,329,511 discuss the possible clinical application of interferon ⁇ for treating autoimmune diseases. Although the above studies may suggest a possible correlation between interferon ⁇ and autoimmune diseases, clinical studies so far have not been conducted to establish a treatment regimen for either Crohn's disease or psoriasis by using anti-interferon ⁇ antibodies.
• the present invention discloses a number of clinical studies for the treatment of psoriasis and/or Crohn's disease. Unique and clinically effective treatment regimens are provided in the present invention.
• the present invention provides a method for the treatment of diseases of the immune system, such as autoimmune diseases.
• the present invention provides a method for treating Crohn's disease in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of an antibody against interferon ⁇ .
• Said treatment reduces the symptoms of the disease, as measured, e.g., by the Crohn's Disease Activity Index (CDAI) score (see Table 1) of said subject.
• the antibody is neutralizing, i.e., neutralizes one or more or all biological activities of interferon ⁇ .
• the antibody is a humanized or human antibody.
• the antibody is HuZAF (see U.S. Patent No. 6,329,511) or an antibody that recognizes the same epitope as HuZAF.
• the present invention also provides a method for treating psoriasis in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of an antibody against interferon ⁇ .
• the treatment reduces the symptoms of the disease, as measured, e.g., by the Psoriasis Area and Severity Index (PASI) (see Table 2) score of said subject.
• the antibody is neutralizing, i.e., neutralizes one or more or all biological activities of interferon ⁇ .
• the antibody is a humanized or human antibody.
• the antibody is HuZAF or an antibody that recognizes the same epitope as HuZAF.
• antibody or “immunoglobulin” is intended to encompass both polyclonal and monoclonal antibodies.
• the preferred antibody is a monoclonal antibody reactive with interferon 7.
• antibody is also intended to encompass mixtures of more than one antibody reactive with interferon 7 (e.g., a cocktail of different types of monoclonal antibodies reactive with interferon 7).
• antibody is further intended to encompass whole antibodies, biologically functional fragments thereof, single-chain antibodies, and chimeric antibodies comprising portions from more than one species, bifunctional antibodies and antibody conjugates and humanized or human antibodies.
• Biologically functional antibody fragments which can also be used, are those peptide fragments derived from an antibody that are sufficient for binding to interferon 7.
• a therapeutically effective amount of a drug or pharmacologically active agent or pharmaceutical formulation is meant a sufficient amount of the drug, agent or formulation to provide the desired effect.
• a “subject,” “individual” or “patient” is used interchangeably herein, which refers to a vertebrate, preferably a mammal, more preferably a human.
• epitopic determinants includes any protein determinant capable of specific binding to an immunoglobulin or an antibody.
• Epitopic determinants usually consist of active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.
• Two antibodies are said to bind to the same epitope of a protein if amino acid mutations in the protein that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other antibody, and/or if the antibodies compete for binding to the protein, i.e., binding of one antibody to the protein reduces or eliminates binding of the other antibody.
• genetically altered antibodies means antibodies wherein the amino acid sequence has been varied from that of a native antibody. Because of the relevance of recombinant DNA techniques to this invention, one need not be confined to the sequences of amino acids found in natural antibodies; antibodies can be redesigned to obtain desired characteristics. The possible variations are many and range from the changing of just one or a few amino acids to the complete redesign of, for example, the variable or constant region. Changes in the constant region will, in general, be made in order to improve or alter characteristics, such as complement fixation, interaction with membranes and other effector functions. Changes in the variable region will be made in order to improve the antigen binding characteristics.
• humanized antibody or “humanized immunoglobulin” refers to an immunoglobulin comprising a human framework, at least one and preferably all complimentarity determining regions (CDRs) from a non-human antibody, and in which any constant region present is substantially identical to a human immunoglobulin constant region, i.e., at least about 85-90%, preferably at least 95% identical.
• CDRs complimentarity determining regions
• all parts of a humanized immunoglobulin, except possibly the CDRs are substantially identical to corresponding parts of one or more native human immunoglobulin sequences. See, e.g. Winter et al., U.S. Patent No.5,225,539; Queen et al., U.S. Patent Nos. 5,530,101, 5,585,089, and 6,180,370 (each of which is incorporated by reference in its entirety).
• chimeric antibody refers to an antibody in which the constant region comes from an antibody of one species (typically human) and the variable region comes from an antibody of another species (typically rodent).
• the present invention provides a method of preventing or treating diseases of the immune system, particularly autoimmune diseases, by using anti-interferon 7 antibodies.
• the autoimmune diseases include, but are not limited to, Addison's disease, autoimmune diseases of the ear, autoimmune diseases of the eye such as uveitis, autoimmune hepatitis, Crohn's disease, diabetes (Type I), epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, ulcerative colitis and vasculitis.
• the present invention provides a method for the treatment of Crohn's disease and other inflammatory bowel diseases such as ulcerative colitis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody recognizing interferon 7.
• the treatment decreases the severity of Crohn's disease as manifested, e.g., by a reduction of the CDAI score of said subject.
• the CDAI score is described in Table 1.
• the CDAI score is reduced by at least 70 points ("response") through treatment disclosed by the present invention. More preferably, the Crohn's treatment of the present invention reduces the CDAI of the Crohn's disease patient by at least 100 points ("enhanced response").
• the CDAI score of the Crohn's sufferer is reduced to an absolute score of 150 points or less ("remission").
• treatment with the anti-interferon ⁇ antibody will lead to responses, enhanced responses or remissions in at least 20% or 30%, but preferably 40% or 50% or even 60%, more preferably 70% or 80% and most preferably 90% or more of the patients.
• this effect should be demonstrated in a clinical trial, for example a phase II or phase III clinical trial, and the increase in responses, enhanced responses or remissions relative to the control group (not treated with the anti-interferon y antibody) should be statistically significant.
• the CDAI score can be measured at about 28 days or 1, 2, 3, 4 or 6 months after beginning or end of treatment, or at some other convenient time.
• the present invention also provides for a method for the treatment of psoriasis in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of an antibody against interferon 7.
• the treatment should cause a reduction of PSAI score of said subject.
• the PASI score is well known to those of skill in treating skin diseases and defined in Table 2.
• Treatment with the antibody should cause a reduction of at least 50% (PASI50) or 75% (PASI75) in the PASI score or even complete or near-complete clearance of the psoriatic lesions.
• PASI50, PASI75 or clearance When applied to a population of psoriasis patients, treatment with the anti-interferon 7 antibody will lead to PASI50, PASI75 or clearance in at least 20% or 30%, but preferably 40% or 50% or even 60%, more preferably 70% or 80% and most preferably 90% or more of the patients. Preferably this effect should be demonstrated in a clinical trial, for example a phase II or phase III clinical trial, and the increase in PASI50, PASI75 or clearance relative to the control group (not treated with the anti-interferon 7 antibody) should be statistically significant.
• the PASI score can be measured at about 28 days or 1, 2, 3, 4 or 6 months after beginning or end of treatment, or at some other convenient time.
• Anti-interferon 7 antibodies for use in the present invention include antibodies that bind to any epitope of interferon 7. They include natural and genetically altered anti- interferon 7 antibodies of all species origins. Non-limiting exemplary natural anti- interferon 7 antibodies include anti-interferon 7 antibodies derived from human, chicken, goats, and rodents (e.g., rats, mice, hamsters and rabbits), including transgenic rodents genetically engineered to produce human antibodies (see, e.g., Lonberg et al., WO93/12227; U.S. Patent No. 5,545,806; and Kucherlapati, et al., WO91/10741; U.S. Patent No.
• Antibodies useful in the present invention also may be made using phage display methods (see, e.g., Dower et al., WO91/17271 and McCafferty et al., WO92/01047, U.S. Patent No. 5,969,108, which are herein incorporated by reference in their entirety).
• the antibodies For use in human patients, the antibodies must bind to human interferon 7.
• the antibodies should have binding affinity for interferon 7 of at least 10 7 M "1 but preferably at least 10 8 M "1 , more preferably at least 10 8 M "1 , most preferably 10 9 M "1 and ideally 10 10 M "1 or higher.
• the affinity of the antibodies may be increased by in vitro mutagenesis using phage display or other methods (see, e.g., Co, et al., U.S. Patent No. 5,714,350, which is herein incorporated by reference in its entirety).
• the antibodies will be neutralizing, that is, they will neutralize at least one but most preferably all biological properties of interferon 7, for example stimulation of MHC expression on suitable cells, activation of macrophages, stimulation of Thl cell development, and anti-viral activity.
• the antibodies will generally inhibit or block binding of interferon 7 of to its cellular receptor.
• the polyclonal forms of these antibodies can be produced in non-human host animals by immunization with human interferon 7.
• the monoclonal antibodies can be produced by immunization and hybridoma methodology. The hybridoma methodology and immunization procedure are well known in the art.
• Recombinant DNA techniques can be used to produce recombinant anti-interferon 7 antibodies, which are also included in the present invention.
• the amino acid sequence of such recombinant antibodies can be identical to the sequences of amino acids found in natural antibodies. Alternatively, it can be genetically altered so that the amino acid sequence has been varied from that of a native antibody.
• Recombinant anti-interferon 7 antibodies include antibodies produced by any expression systems including both prokaryotic and eukaryotic expression systems. Exemplary prokaryotic systems are bacterial systems that are typically capable of expressing exogenously introduced sequences at large quantity.
• Illustrative eukaryotic expression systems include fungal expression systems, viral expression systems involving eukaryotic cells such as insect cells, plant cells and especially mammalian cells (such as CHO cells and myeloma cells such as NSO and SP2/0) which are well-known to those of skill in the art.
• the antibodies may also be produced by chemical synthesis. However they are produced, the antibodies will be purified by art-known methods such as filtration, chromatography (e.g., affinity chromatography such as by protein A, cation exchange chromatography, anion exchange chromatography, and gel filtration).
• the minimum acceptable purity of the antibody for use in pharmaceutical formulations will be 90%, with 95% preferred, 98% more preferred and 99% or higher most preferred.
• the genetically altered anti-interferon 7 antibodies used in the present invention include humanized antibodies that bind to and neutralize interferon 7. Examples of these humanized antibodies are disclosed in the U.S. Patent No. 6,329,511, which is hereby incorporated by reference in its entirety.
• An exemplary, preferred humanized anti-interferon 7 antibody is HuZAF, comprising a mature light chain variable region, whose amino acid sequence is amino acids 21 through 128 of SEQ ID NO 1, and a mature heavy chain variable region, whose amino acid sequence is amino acids 20 through 136 of SEQ ID NO 2.
• Other preferred antibodies include those that bind to the same epitope of interferon 7 as HuZAF, especially other humanized forms of the AF2 antibody described in U.S. Patent No.
• the antibody may be of any of the recognized isotypes, but the four IgG isotypes are preferred, with IgGl especially preferred.
• Antibodies with constant regions mutated to have reduced effector function for example the IgG2m3 and other IgG2 mutants described in U.S. Patent No. 5,834,597 (which is incorporated by reference in its entirety), are another preferred choice.
• the genetically altered anti-interferon 7 antibodies also include chimeric antibodies that bind to and neutralize interferon 7.
• the chimeric antibodies comprise a variable region derived from a mouse or rat and a constant region derived from a human so that the chimeric antibody has a longer half-life and is less immunogenic when administered to a human subject.
• the method of making chimeric antibodies is known in the art.
• fragments of the above-described anti-interferon 7 antibodies which retain the binding specificity to interferon 7, are also included in the present invention.
• Examples include, but are not limited to, the heavy chains, the light chains, and the variable regions as well as Fab and (Fab') 2 of the antibodies described herein.
• the genetically altered antibodies also include modified anti-interferon 7 antibodies that are functionally equivalent to above antibodies and antibody fragments.
• Modified antibodies providing improved stability and/or therapeutic efficacy are preferred.
• modified antibodies include those with conservative substitutions of amino acid residues, and one or more deletions or additions of amino acids which do not significantly deleteriously alter the antigen binding utility. Substitutions can range from changing or modifying one or more amino acid residues to complete redesign of a region as long as the therapeutic utility is maintained.
• Antibodies of this invention can be can be modified post-translationally (e.g., acetylation, and phosphorylation) or can be modified synthetically (e.g., the attachment of a labeling group). Fragments of these modified antibodies that retain the binding specificity can also be used.
• the present invention provides a pharmaceutical formulation comprising the antibodies described herein.
• Pharmaceutical formulations of antibodies are prepared for storage by mixing the antibodies having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers, in the form of lyophilized or aqueous solutions.
• Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers, amino acids, carbohydrates, chelating agents, sugar, and other standard ingredients known to people skilled in the art (Remington's Pharmaceutical Science 16 th edition, Osol, A. Ed. 1980).
• the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
• Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
• Active ingredients of the above pharmaceutical formulation may also be entrapped in microcapsules, in colloidal drug delivery systems (for example, liposome, albumin microspheres, microemulsions, nano-particles and nanocapsules), in macroemulsions, or in sustained-release preparation.
• colloidal drug delivery systems for example, liposome, albumin microspheres, microemulsions, nano-particles and nanocapsules
• macroemulsions or in sustained-release preparation.
• the formulation to be used for in vivo administration is usually stored at 2 to 8 °C.
• the formulations often contain no preservatives and should be used within 4, 12 or 24 hours of withdrawal from the vial and dilution into saline.
• the formulation is preferably administered intravenously or subcutaneously with or without filtration.
• humanized anti-interferon 7 antibody, HuZAF is stored in a single-use glass vial containing 1.0 mL of HuZAF at a concentration of 50 mg/mL in an isotonic buffer of histidine, glycine, and Polysorbate 80, at pH 6.0.
• concentrations from 1 to 10 mg/mL e.g., 1, 2, 5 or 10
• 20 to 50 mg/mL e.g., 20, 30, 40 or 50
• 60 to 100 mg/mL e.g., 60, 70, 80, 90 or 100
• the antibodies prepared in a pharmaceutical formulation can be administered by any suitable route including oral, rectal, nasal, topical (including transdermal, aerosol, buccal and sublingual), parental (including subcutaneous, intramuscular, intravenous and intradermal) or by inhalation therapy. It will also be appreciated that the preferred route may vary with the condition and age of the recipient.
• the pharmaceutical formulation is delivered via intravenous infusion, for example over 30 or 60 minutes, such that a therapeutically effective amount of said composition is delivered via systemic absorption and circulation.
• the pharmaceutical formulation is delivered via subcutaneous injection, such that a therapeutically effective amount of said composition is delivered via systemic absorption and circulation.
• the formulation may also be delivered as an intravenous bolus.
• a therapeutically effective amount of above formulations depends on the severity of the Crohn's disease or psoriasis, the patient's clinical history and response, and the discretion of the attending physician.
• the composition is suitably administered to the patient at one time or over a series of treatments.
• the initial candidate dosage may be administered to a patient.
• the proper dosage and treatment regime can be established by monitoring the progress of therapy using conventional techniques known to the people skilled of the art.
• the amount of active ingredients that may be combined with the carrier materials to produce a single dosage form will vary depending upon the subject treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific composition employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy, and can be determined by those skilled in the art.
• an exemplary effective dose for the treatment of Crohn's disease or psoriasis ranges between about 0.01 mg/kg to about 100 mg/kg, preferably between about 0.1 mg/kg to about 10 mg/kg, and more preferably about 0.5 mg/kg to about 5 mg/kg.
• the dose is expected to be well-tolerated based on the pre-clinical trial studies in animals and humans.
• Preferred dose levels include 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 5 mg/kg and 10 mg/kg.
• An initial higher "loading dose" of the antibody may be followed by lower maintenance doses, for example 2, 4, 5 or 10 mg/kg may be followed by 0.1, 0.5, 1 or 2 mg/kg.
• the loading dose may be administered intravenously followed by maintenance doses administered subcutaneously.
• Fixed unit doses may also be administered, e.g., 50, 100 or 200 mg.
• the regimen of the treatment of Crohn's disease and psoriasis can vary significantly.
• a patient is administered at least a single dose of said pharmaceutical formulation.
• Additional doses can be administered for multiple times (for example, once, twice, three times, four times, five times, 6-10 times or more), e.g., daily, two or three times a week, biweekly, or monthly, every 6 weeks, or every 2 or 3 months.
• the period of treatment may be, e.g., 1, 2, 4 or 6 weeks, or 2, 3, 4, 6 or 12 months or indefinitely.
• the patient may receive 2, 3, 4 or more courses of treatment if the disease relapses.
• a single dose of anti- interferon 7 antibody is administered to a patient by intravenous infusion. After 4 weeks, the CDAI score of the patient receiving the treatment is evaluated. If a reduction of more than 70 points is observed, the patient will receive a dose that is 50% of the initial single dose in a regimen of one dose every 4 weeks. The 50% dose is needed to avoid drug accumulation due to the 2 to 3 week half-life of HuZAF.
• the initial dose may be 0.1 , 1, 4 or 10 mg/kg.
• the combination of intravenous infusion and subcutaneous injection of the antibodies are used for the treatment of Crohn's disease.
• a patient is both subcutaneously injected and intraveneously infused (preferably, for over 30 minutes) with the antibodies.
• a patient receives antibodies as an IV infusion on Day 1. Beginning on Day 29, the patient receives one SC dose every 4 weeks for 3 doses (Day 29, Day 57, and Day 85).
• CDAI evaluation is performed at Day 28 and each treatment day and Day 1 13. Patients are monitored to determine if additional SC administration is needed to maintain the response.
• Examples of the treatment regimen include, but are not limited to, (1) about 1.0 mg/kg IV followed by about 0.1 mg/kg SC; (2) about 1.0 mg/kg IV followed by about 1.0 mg/kg SC; (3) about 4.0 mg/kg IV followed by about 0.1 mg/kg SC; (4) about 4.0 mg/kg IV followed by about 1.0 mg/kg SC.
• CDEIS Crohn's Disease Endoscopic Index of Severity
• CEP C-reactive protein
• IL-6 interleukin-6
• IP-10 interferon- ⁇ - inducible protein- 10
• IFN- ⁇ interferon- ⁇
• Biopsies are taken from active lesions, where permitted, biopsy materials are evaluated for inflammatory activity.
• skin biopsies are performed on selected patients to evaluate the mechanism of action of the anti-interferon ⁇ antibodies.
• the Psoriasis Area Severity Index (PASI) score is collected to assess any changes in disease activity over time.
• PASI Psoriasis Area Severity Index
• HuZAF the arbitrary name given to a particular humanized anti-IFN-7 antibody developed by the assignee of the present invention, is the humanized form of a murine anti-human IFN- 7 antibody (AF2) directed against recombinant human IFN-7.
• HuZAF prevents IFN-7 from binding to its cellular receptors, thereby neutralizing IFN-7-mediated activities, including induction of MHC class II molecule expression, viral protection, and inhibition of proliferation of certain cells.
• the isotype of the HuZAF heavy chain is human IgGl; the light chain is human kappa.
• This example describes the overall plan of the clinical studies of anti-interferon 7 antibodies.
• the "ZAF xxx" nomenclature is an arbitiary numbering system devised by the assignee of the present invention to designate its various HuZAF antibody clinical studies.
• ZAF 702 Phase I/II double-blind, placebo-controlled, single and multiple IV dose, dose escalation study in moderate to severe CD patients
• ZAF 707 Phase II, double-blind (except to the site pharmacist), randomized, placebo-controlled study of HuZAF administered intravenously as a loading dose followed by multiple SC maintenance doses.
• ZAF 708 Phase II, randomized, double-blind, placebo-controlled study to determine the safety and efficacy of HuZAF in patients with moderate to severe Crohn's disease
• ZAF 705 Phase I double-blind, placebo-controlled, single IV dose, dose escalation study in patients with plaque psoriasis
• ZAF 706 Phase I/II double-blind, placebo-controlled, multiple SC doses, dose escalation study in patients with plaque psoriasis
• ZAF-701 was a single-dose, phase I study designed to assess the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effect of HuZAF administered as an intravenous infusion to 22 healthy volunteers (18 male and 4 female).
• PK pharmacokinetics
• PD pharmacodynamic
• HAHA Human anti-humanized antibody
• the PD effect of HuZAF was measured using an antigen challenge to mumps and Candida antigens.
• Subjects were pre-screened for delayed-type hypersensitivity (DTH) responses to these antigens prior to dosing with HuZAF.
• DTH delayed-type hypersensitivity
• At 48 hours after dosing reduced DTH responses were seen in most of the tested subjects, especially if their screening DTH responses had been vigorous.
• the DTH responses were less than half the size of those observed at screening in 23 of 29 (79%) evaluable tests.
• the median post-treatment lesion size was 9% of the screening size, which represents a 91% reduction in lesion size. This result indicates the effectiveness of anti-interferon 7 antibodies in a model of inflammation, especially of the skin, such as psoriasis.
• Example 4 This example describes a clinical study of phase I/II, double-blind, placebo- controlled, single- and multiple-dose, dose escalation study of a humanized anti- interferon- ⁇ antibody (HuZAF) in patients with moderate to severe Crohn's Disease.
• Humanized anti- interferon- ⁇ antibody HuZAF
• HuZAF in an isotonic buffer composed of L-histidine, glycine, and
• Diluent If the volume to be administered is ⁇ 50 mL, dilute the drug to 50 mL in 0.9% saline. If the volume is 50 mL, infuse without dilution.
• formulation contains no preservative and is used within 12 hours of withdrawal from the vial and dilution (if any) into saline.
• the formulation must be administered intravenously without filtration.
• Protocol ZAF-702 was a Phase I/II, double-blind, randomized, placebo-controlled, single- and multiple dose, dose-escalation study that was conducted at up to 10 investigational sites in 2 stages.
• Stage A up to 48 patients with moderate to severe Crohn's disease between the ages of 18 and 65 received a single dose of HuZAF by intravenous infusion at one of 3 dose levels (0.1, 1, 4 mg/kg) or placebo.
• 3 dose levels 0.1, 1, 4 mg/kg
• Up to 8 additional patients may receive HuZAF/placebo if treatment- related adverse events (AE) of clinical concern caused dose escalation to cease at a given dose level.
• the patients were randomized to receive HuZAF or placebo in a 3: 1 ratio. Patients must have had a diagnosis of Crohn's disease for at least 6 months and have received prior treatment for their CD (excludes treatment-na ⁇ ve patients), with a Crohn's Disease Activity Index (CDAI) score of > 250 and ⁇ 450.
• CDAI
• Stage B the patients were re-randomized to receive either 3 doses of HuZAF at a level that is 50% of the single dose received in Stage A of the study, or 3 doses of placebo, in a regimen of one dose every 4 weeks.
• the 50% dose was needed to avoid drug accumulation due to the anticipated 2- to 3 -week half-life of HuZAF.
• the patients were randomized to receive HuZAF or placebo in a 3:1 ratio.
• Stage A a Phase I/II, double-blind, placebo-controlled, dose escalation study was conducted to measure the safety and efficacy of a single IV infusion of HuZAF in patients with moderate to severe active Crohn's disease (CD). Forty-five patients (of whom 42 were evaluable) with CD who had CDAI scores of more than 250 and less than 450 were randomized to receive one of 3 dose levels of HuZAF (0.1, 1.0, or 4.0 mg/kg) or a single dose of placebo.
• Study endpoints at 4 weeks postdosing were (1) clinical response (decrease of CDAI score more than or equal to 70 points from baseline), (2) remission (CDAI score of less or equal to 150), (3) enhanced response (decrease of CDAI score more than or equal to 100 points), and (4) safety.
• the results showed that demographics and baseline disease characteristics were comparable for the 4 groups. Adverse events were distributed among the 4 groups; the 3 reported SAEs were considered to be related to disease. Increased doses of HuZAF correlated with higher rates of clinical response and greater numbers of remissions. Likewise, the percent of patients with enhanced response was higher as dose levels increased (Table 4).
• Stage B patients who responded in Stage A were re-randomized to receive 50% of stage A dose or placebo every 4 weeks for 3 doses.
• study day 113 most patients retained their response or remission, whether they received additional doses of HuZAF or placebo, indicating that responses and remissions induced by HuZAF are generally long-lasting.
• Table 4 Number (Percent) of Patients with Clinical Response and Remission at
• This example describes a Phase I, double-blind, placebo-controlled, single-dose, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of HuZAF, a humanized anti-interferon-gamma antibody, in patients with plaque psoriasis.
• Comparative Drug Placebo, isotonic buffer composed of histidine, glycine, and
• formulation contains no preservative and must be used within 12 hours of withdrawal from the vial.
• the formulation must be administered intravenously without filtration.
• ZAF-705 was a Phase I, double-blind (but not to the sponsor and the site pharmacist), randomized, single dose, dose escalation trial of HuZAF that is conducted in up to 3 centers in the United States (US) and Canada. Up to 35 patients with plaque psoriasis who are 18 years of age or older received a single dose of 0 (placebo), 0.1, 1.0, 3.0, or 10.0 mg/kg HuZAF by intravenous infusion. The objectives of the study were to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single intravenous dose of HuZAF and the ability of HuZAF to decrease disease activity.
• PK pharmacokinetics
• PK pharmacokinetic
• HAHA human anti-humanized antibody
• Psoriasis Area Severity Index (PASI) (Table 2) was collected to assess any changes in disease activity over time.
• the PASI score of the tested patients was improved after the treatment with HuZAF in a dose-dependent manner. For instance, at D15, about 25% patients who were treated with HuZAF achieved a more than 50% and 75% reduction of PASI scores. The treatment with 3 mg/kg HuZAF gave rise to a mean reduction of 31.9% in PASI scores while the treatment with 0.1 mg/kg HuZAF gave rise to a mean reduction of 4.3% in PASI scores. One patient had a reduction of PASI scores as high as 76.5%. At D29, about 25% patients who were treated with HuZAF achieved a more than 50% reduction of PASI scores. The treatment with 3 mg/kg HuZAF gave rise to a mean reduction of 21.9% in PASI scores while the treatment with 0.1 mg/kg HuZAF gave rise to a mean reduction of 8.3% in PASI scores.
• This example describes a Phase I/II, double-blind, placebo-controlled, multiple- dose, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and biologic activity of a humanized anti-interferon- ⁇ monoclonal antibody (HuZAF) in patients with plaque psoriasis
• Humanized anti-interferon- ⁇ monoclonal antibody HuZAF
• ZAF-706 is a Phase I/II, double-blind (not to the sponsor and the site pharmacist), randomized, multiple-dose, dose escalation trial of HuZAF that is conducted in up to 4 centers in Canada. Up to 35 patients with moderate to severe plaque psoriasis who are 18 years of age or older are randomized to receive subcutaneous (SC) injections of placebo or HuZAF (0.1, 0.5, or 1.0 mg/kg). Up to 5 additional patients may receive HuZAF or placebo if treatment-related adverse events (AE) of clinical concern cause dose escalation to cease at any given dose level.
• SC subcutaneous
• HuZAF 0.1, 0.5, or 1.0 mg/kg
• Up to 5 additional patients may receive HuZAF or placebo if treatment-related adverse events (AE) of clinical concern cause dose escalation to cease at any given dose level.
• the objectives of the study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of HuZAF when administered as multiple SC injections. The ability of Hu
• Patients must not have received systemic therapy for their psoriasis (either approved or investigational) within 30 days prior to study entry. Patients must not have had prior antibody treatment within 6 months. Patients using topical agents must have been on a stable dose for at least 2 weeks prior to study entry. New topical agents are allowed only if lesions on the scalp, face, or groin worsen. A chest x-ray and tuberculin skin test is performed before the start of the study to rule out latent tuberculosis; patients who test positive are excluded from the study.
• Patients are randomized to receive placebo or HuZAF at the following dose levels: 0.1, 0.5, and 1.0 mg/kg. At each dose level, 5 patients are randomized in a ratio of 4 HuZAF patients to one placebo patient. If 3 out of 4 HuZAF patients at a given dose level experience no study-related AEs of clinical concern within 7 days after receiving the first dose, escalation to the next dose level will occur. If 2 of 4 HuZAF patients experience a study- related AE of clinical concern within 7 days of the first dose, 3 additional patients will be randomized in a 2: 1 ratio (HuZAF:placebo) at that same dose level.
• Plasma samples are collected at specified time periods throughout the study for the determination of PK and anti-antibody (anti-Ab) levels. A complete PK profile is obtained at all dose levels.
• Summary statistics include mean, median, standard deviation, and the minimum and maximum changes in disease state as measured by calculating the change from baseline of the PASI and PGA scores.
• Pharmacokinetic results are presented by dose level in tables and graphs. Adverse events and clinical and laboratory assessments are presented in tables.
• This example describes a Phase II, double-blind, placebo-controlled study to determine the safety and efficacy of a humanized anti-interferon- ⁇ monoclonal antibody (HuZAF) administered to patients with moderate to severe Crohn's disease
• Humanized anti-interferon- ⁇ monoclonal antibody HuZAF
• Test Drug in an isotonic buffer composed of histidine, glycine, and
• Comparative Drug Placebo (isotonic buffer composed of histidine, glycine, and
• Diluent IV: Dilute the test article to 50 mL in 0.9% saline.
• the formulation contains no preservative, and must be administered and Administration: without filtration.
• the formulation should be used within 12 hours of withdrawal from the vial and dilution into saline.
• SC The formulation must be used within 3 hours of withdrawal from the vial.
• ZAF-707 is a Phase II, double-blind (except to the site pharmacist), randomized, placebo-controlled study of HuZAF administered intravenously as a loading dose followed by multiple SC maintenance doses that is conducted at up to 25 investigational sites in the US, Canada, and Europe.
• the objective of the study is to evaluate the safety and efficacy of an IV loading dose of HuZAF for induction of a clinical response, defined as a decrease of > 100 points in the Crohn's Disease Activity Index (CDAI) score at Day 29.
• An additional CDAI evaluation is also performed at Day 43 after administration of the IV loading dose and one SC maintenance dose.
• the ability of HuZAF to maintain the response with subsequent SC administration is also evaluated.
• PK pharmacokinetic
• anti-Ab anti-antibody
• a complete PK profile is obtained at all dose levels for selected patients.
• patients are scored using the CDAI and Inflammatory Bowel Disease Questionnaire (IBDQ). Circulating levels of C-reactive protein (CRP) are determined.
• Clinical response is defined as a decrease of > 100 points in CDAI score from baseline levels without an accompanying increase in dose of concomitant medications or addition of a new medication as therapy for the disease. The primary endpoint is clinical response at Day 29.
• CDAI scores are evaluated at specified time points throughout the study to assess maintenance of response. IBDQ scores are used to evaluate patients' quality of life.
• Demographics and baseline characteristics of all patients are summarized collectively and by treatment group. Patients are pooled across sites when partitioned by treatment group and pooled across treatment groups when compared by site.
• the characteristics of interest include age, sex, ethnicity, baseline CDAI and IBDQ scores, CRP value, disease duration, and smoking status.
• Summary statistics include response rates and associated 95% confidence intervals, as well as mean, standard deviation (or error, as appropriate), median, minimum and maximum changes in CDAI and IBDQ scores, and serum levels of CRP from respective baselines to appropriate visits. The magnitude and direction of the changes are compared between treatment groups.
• Anti-Ab samples are collected from all patients, and all of the samples will be analyzed. PK samples are collected from odd-numbered patients only; PK samples collected from placebo patients are not analyzed for PK or used for any other purpose.
• the percent of patients who achieve remission (absolute CDAI ⁇ 150) will also be compared between the placebo and the active treatment groups.
• the study is not powered to detect statistically significant differences among the five IV-to-SC dosing regimens. Due to anticipated losses of non-responders, fewer than 30 patients per arm are likely.
• This example describes a Phase II, double-blind (except to the site pharmacist), randomized, placebo-controlled study to be conducted at up to 25 investigational sites in Europe. Up to 120 patients with moderate to severe CD will receive placebo or HuZAF at a dose of 4 or 10 mg/kg intravenously.
• Subsequent patients are randomized to receive one infusion of the test article during the DSMB review. If no major concerns regarding the extent and type of AEs encountered arise and the recommendation to proceed to the next group of patients is made, the remaining patients will be randomized to receive 2 doses of the test article (Group II). An email and a written letter will be sent out to notify each study site to begin enrollment into Group II. Prior to receiving this notification, the sites should continue to enroll patients into Group I.
• Patients in Group II receive the first IV infusion of placebo or HuZAF (4 or 10 mg/kg) at Study Day 0. On Study Day 28, after completing all required study assessments, patients receive their second IV infusion of placebo or HuZAF (4 or 10 mg/kg). Patients who are treatment failures (defined below) will leave the study, receive appropriate rescue medications, and be followed for safety.
• a treatment failure is defined as a patient whose CDAI score increases > 100 points from the lowest CDAI score at any time (absolute CDAI score must be greater than 150 points) or increases to a score of > 450 points.
• Test Drug HuZAF (fontolizumab)
• Patient Population Patients with moderate to severe active Crohn's disease (CD) who received prior treatment for their CD. Patients previously treated with HuZAF are excluded.
• CD Crohn's disease
• Inclusion Criteria Patients are eligible for inclusion if they are 18 to 70 years old, have received treatment for CD for at least 6 months prior to study entry, have been diagnosed as having moderate to severe active CD (CDAI score > 250 and ⁇ 450), agree to use adequate contraception, have a negative pregnancy test at study entry (women of child-bearing potential only), understand the purpose and risks of the study, and provide informed consent.
• CDAI score > 250 and ⁇ 450 moderate to severe active CD
• Dose Regimen/Route of Group I A minimum of 30 patients receives a single dose of Administration: placebo or HuZAF (4 or 10 mg/kg) given intravenously over 30 minutes.
• Group II The remaining patients receive a single dose of placebo or HuZAF (4 or 10 mg/kg) given intravenously over 30 minutes once every 28 days for 2 doses.
• Dosage Form and Single-use glass vials containing 1.0 mL of HuZAF at a Strength/Formulation concentration of 50 mg/mL in an isotonic buffer of histidine, glycine, and Polysorbate 80, at pH 6.0.
• Placebo consists of the formulation buffer.
• the formulation contains no preservative, and must be administered without filtration.
• the formulation should be used within 12 hours of withdrawal and dilution into saline.
• Duration of Treatment Group I Each patient has 8 visits during the study: one baseline and Follow up: visit, one treatment visit, 4 study visits, one follow-up visit, and one long-term follow-up visit, which may be in the form of a telephone call.
• Group II Each patient has 9 visits during the study period: one baseline visit, 2 treatment visits, 4 study visits, one follow-up visit, and one long-term follow-up visit, which may be in the form of a telephone call.
• the total duration of the study for each patient is approximately 7 months.
• Sample Size Up to 120 patients
• Number of Sites Up to 25 investigational sites in Europe
• Statistical Methods All randomized patients with an initiated infusion and valid baseline assessments are analyzed, regardless of the number of infusions that are completed ("intention-to-treat" approach). Incidences are compared using Fisher's exact test or the Cochran Mantel-Haenzel test. The changes from baseline of the continuous variables (CDAI scores and CRP values) are compared using Student's t-test or analysis of variance techniques. For time-related variables, Kaplan-Meier plots and log-rank tests may be employed.
• the total number of patients for the study is 120.
• the study is not powered to detect statistically significant differences between the 2 active dosing regimens.
• Duration of clinical response where duration of clinical response is delimited by the visits at which the CDAI score improves by 100 or more points from baseline and later deteriorates to within 50 points of baseline
• Pharmacodynamic Endoscopy may be performed at selected sites.
• CDEIS scores are Measurements used to assess endoscopic improvement of CD. Exploratory PD markers are assessed at selected sites. The analysis of IFN- ⁇ - inducible chemokines/cytokines in the serum (such as IP-10 and MIG) and CXCR3+ lymphocytes in the peripheral blood is performed.
• Pharmacokinetic Blood samples are collected from patients for PK analysis at Measurements selected sites.
• Anti-Ab Assessments Blood samples are collected from all patients for measurement of anti-Ab levels.
• Anti-diarrhea/opiate therapy at least once: x 30
• Psoriasis Area and Severity Index Psoriasis Area and Severity Index
• BSA body surface area
• the PASI score is calculated using the following formula
• PASI 0 l(E h +I h + D h )A h + 0 2 (E u +I U + D U )A U + 0 3(E t +I t + Dt)A, + 0 4(E, +1, + D,)A, ,
• A is assigned a numerical value based on the extent of lesions in a given site
• the PASI varies in steps of 0 1 units from 0 0 to 72 0
• the highest score represents complete erythroderma of the severest possible degree
• segmental data will be collected for the following 5 segments rectum, sigmoid and left colon, transverse colon, right colon (and cecum), and lleum
• CDEIS Crohn's Disease Endoscopic Index of Severity
• CDEIS Crohn's Disease Endoscopic Index of Severity

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Neurology (AREA)
• Hematology (AREA)
• Physical Education & Sports Medicine (AREA)
• Endocrinology (AREA)
• Rheumatology (AREA)
• Emergency Medicine (AREA)
• Biochemistry (AREA)
• Ophthalmology & Optometry (AREA)
• Pain & Pain Management (AREA)
• Biomedical Technology (AREA)
• Dermatology (AREA)
• Gastroenterology & Hepatology (AREA)
• Transplantation (AREA)
• Obesity (AREA)
• Neurosurgery (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Urology & Nephrology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Publications (2)

Family

ID=29552737

Family Applications (1)

Country Status (5)

Cited By (5)

Families Citing this family (3)

Citations (9)

Family Cites Families (3)

• 2003
  • 2003-05-16 WO PCT/US2003/015874 patent/WO2003097082A2/en active Application Filing
  • 2003-05-16 CA CA002486147A patent/CA2486147A1/en not_active Abandoned
  • 2003-05-16 EP EP03753102A patent/EP1506002A4/en not_active Withdrawn
  • 2003-05-16 JP JP2004505078A patent/JP2005529152A/ja active Pending
  • 2003-05-16 AU AU2003231802A patent/AU2003231802A1/en not_active Abandoned

Patent Citations (12)

Non-Patent Citations (1)

Also Published As

Similar Documents